Nebenwirkungen · Fuzeon
Fuzeon 90 mg/ml powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 6–7
HOS-112418 · Präparat HOS-093667
Injection site reactions (ISRs) were the most frequently reported adverse reaction and occurred in 98% of the patients (Table 3). The vast majority of ISRs occurred within the first week of Fuzeon 6 administration and were associated with mild to moderate pain or discomfort at the injection site without limitation of usual activities. The severity of the pain and discomfort did not increase with treatment duration. The signs and symptoms generally lasted equal to or less than 7 days. Infections at the injection site (including abscess and cellulitis) occurred in 1.5% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-23T14:24:00Z · SHA-256 e89d317a43084b88c577a5e2fa9e8f995c2b6672ed7d5ae08eb316c0043e17cf · Passage 473bfecf80a3fb6af22aea5197f02115cab0c30c4b440efca1e1c800ed4b5780 · Zeichen 3558–4196 im Abschnitt